Discontinuation of diabetes and lipid-lowering medications after bariatric surgery at Veterans Affairs medical centers.

Published

Journal Article

BACKGROUND: Bariatric surgery has largely been performed on middle-age female populations and been associated with significant medication discontinuation; however, it is unknown whether similar medication discontinuation rates could be achieved in men. The purpose of the present analysis was to examine the discontinuation rate of diabetes or lipid-lowering medications and the patient factors associated with medication discontinuation among veterans undergoing bariatric surgery. METHODS: We identified the demographic and health status information for 284 veterans with diabetes and 298 veterans with hyperlipidemia who had undergone bariatric surgery at 1 of 12 Veterans Affairs bariatric centers in 2000 to 2006 from the Veterans Affairs National Surgical Quality Improvement Program data. We also identified the medications that had been prescribed and discontinued using the Veterans Affairs administrative data. Medication discontinuation was estimated using a logistic regression model. RESULTS: Of the 284 veterans with diabetes and 298 with hyperlipidemia, 52% and 40% had discontinued their medications at 1 year, respectively. The veterans with diabetes were more likely to discontinue medication if they had been taking oral hypoglycemic agents alone (odds ratio 2.77, P <.001) than were those taking insulin or oral hypoglycemic agents and insulin. The veterans with hyperlipidemia were more likely to discontinue medication if they had only been taking fibrates (odds ratio 6.15, P <.01) than were those veterans taking statins and fibrates. CONCLUSION: Bariatric surgery led to significant medication discontinuation within 1 year for high-risk veterans with diabetes or hyperlipidemia.

Full Text

Duke Authors

Cited Authors

  • Maciejewski, ML; Livingston, EH; Kahwati, LC; Henderson, WG; Kavee, AL; Arterburn, DE

Published Date

  • November 2010

Published In

Volume / Issue

  • 6 / 6

Start / End Page

  • 601 - 607

PubMed ID

  • 20965791

Pubmed Central ID

  • 20965791

Electronic International Standard Serial Number (EISSN)

  • 1878-7533

Digital Object Identifier (DOI)

  • 10.1016/j.soard.2010.07.005

Language

  • eng

Conference Location

  • United States